Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

11,350articles mentioning institutions

22,378institution mentions

9,137distinct institutions extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted institutions

Showing 8,221–8,280 of 9,137, ordered by supporting articles. Choose a institution to see its evidence.

University of California, Santa Cruz1 University of California-Irvine Machine Learning Repository1 University of Cape Town Knowledge Translation Unit1 University of Ceylon Colombo medical school1 University of Chicago Institutional Review Board1 University of Chicago Medicine1 University of Chile1 University of Cincinnati Cancer Center1 University of Colorado Human Immune Monitoring Shared Resource Facility1 University of Colorado School of Medicine1 University of Cordoba1 University of Debrecen1 University of Dhaka Institute of Health Economics1 University of Durham1 University of East Anglia1 University of Exeter Medical School1 University of Exeter Public Health and Sport Sciences1 University of Florence1 University of Florida College of Dentistry1 University of Florida College of Medicine1 University of Florida Institutional Animal Care and Use Committee1 University of Florida, Gainesville1 University of Giessen1 University of Glasgow School of Medical and Life Sciences Ethics Committee1 University of Gondar Comprehensive Specialized Hospital Tertiary Eye Care and Training Center1 University of Gondar, Comprehensive and Specialized Hospital1 University of Gothenburg1 University of Gothenburg, Sweden1 University of Groningen1 University of Health Sciences Research and Training Hospital1 University of Houston Institutional Review Board1 University of Huddersfield1 University of Hull1 University of Illinois1 University of Illinois Hospital in Chicago1 University of Illinois at Urbana-Champaign1 University of Indonesia–Cipto Mangunkusumo Hospital1 University of Iowa Holden Comprehensive Cancer Center1 University of Jyväskylä1 University of Kansas Medical Centre1 University of Karachi1 University of Kent1 University of Kentucky1 University of Kisangani1 University of KwaZulu-Natal Biomedical Research EC1 University of Kwazulu-Natal1 University of Lahore1 University of Lancashire1 University of Latvia Statistics Laboratory1 University of Lausanne1 University of Limerick Education and Health Sciences Research Ethics Committee1 University of Limoges1 University of Liverpool1 University of London1 University of Manchester Research Ethics Committee1 University of Maryland Medical Center1 University of Maryland, Baltimore1 University of Miami Institutional Review Board1 University of Michigan Medical Institutional Review Board1 University of Michigan Medical School1

View all 9,137 institutions on one page

Articles mentioning institutions

11,350 articles · page 312 of 946

521 Correlative analysis of a phase I study of autologous activated NK Cells ± rhIL-15 in children and young adults with refractory solid tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

93.7%

National Cancer Institute NCI rhIL-15 solid tumors relapsed/refractory solid tumors NK cell immunotherapies cyclophosphamide

…his study was approved by the Institutional Review Board of the National Cancer Institute (NCI) at the NIH, approval number 13-C-0152, and was conducted …

522 A clinical study on iNeo-Vac-P01: a personalized neoantigen immunotherapy for postoperative recurrence prevention in pancreatic cancer

jitc · abstract · 2025-11-04 · 2 matching annotations

95.3%

Zhejiang Provincial People’s Hospital iNeo-Vac-P01 pancreatic ductal adenocarcinoma (PDAC)

…n-label, single-arm clinical trial ( NCT04810910), conducted at Zhejiang Provincial People’s Hospital, enrolled PDAC patients who initiated treatment with iNeo-Vac-P…

536 Phase 1 trial of tumor-infiltrating lymphocyte (TIL) therapy in recurrent glioblastoma: A single-center experience using cells derived from primary surgical specimens

jitc · abstract · 2025-11-04 · 2 matching annotations

97.5%

Second Affiliated Hospital of Soochow University The Second Affiliated Hospital of Soochow University cyclophosphamide hydroxychloroquine Glioblastoma left frontal lobe glioblastoma sintilimab Innovent GB

… open-label, nonrandomized clinical trial ( NCT04943913) at the Second Affiliated Hospital of Soochow University to evaluate the safety and efficacy of TIL therapy in recurrent…

537 Targeting diffuse intrinsic pontine glioma with IL-7Rα-enhanced B7-H3 (CMD03) chimeric antigen receptor T cell: preliminary results from phase 1 clinical trial

jitc · abstract · 2025-11-04 · 2 matching annotations

97.0%

Chulalongkorn University Cancer Immunol Immunother dexamethasone CMD03 anakinra B7-H3 Diffuse intrinsic pontine glioma (DIPG)B7-H3-targeting DIPG

…DIPG ( NCT06221553). Approval was granted by the IRB committee, Chulalongkorn University (COA#1647/2024). Dose levels include 1×107, 3×107, and 1×108 CA…

54 Development and characterization of cytokine-based classifiers to predict response to immunotherapy using an ex vivo live tumor fragment platform

jitc · abstract · 2025-11-04 · 2 matching annotations

79.9%

Voabil et al.NCT05478538 αPD-1 αPD-L1 αCTLA-4

…ovide external validation of a weighted classifier published by Voabil et al.1 for predicting response to PD-1 blockade. Additionally, we tra…

552 Feasibility and tolerability of a CD4 re-directed chimeric antigen receptor T cell therapy (CD4CAR) in hematological malignancies: Initial results from multi-institutional first-in-human (FIH) trials

jitc · abstract · 2025-11-04 · 2 matching annotations

98.3%

Indiana University University of Miami FDA AML bendamustine acute myeloid leukemias chronic myelomonocytic leukemia fludarabine/cyclophosphamide TCM venetoclax+3 more

…CT06197672Ethics Approval The study obtained ethics approval by Indiana University and University of Miami IRB and participants gave informed cons…

553 A phase I clinical trial of allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B cell malignancies: an interim analysis

jitc · abstract · 2025-11-04 · 2 matching annotations

94.1%

Baylor College of Medicine BCM graft-versus-host disease B cell malignancies IL-15 ALL-1 NHL-2 ALL-3

…al This study was approved by the Institutional Review Board at Baylor College of Medicine (BCM; H-44526).…

556 Transposon-based BAFF CAR-T cells (LMY-920) for treatment of non-hodgkin lymphoma (NHL), chronic lymphocytic lymphoma (CLL) and multiple myeloma (MM)

jitc · abstract · 2025-11-04 · 2 matching annotations

92.2%

Case Comprehensive Cancer Center Cleveland Clinic’s Institutional Review Board fludarabine lymphoma myeloma cyclophosphamide LMY-920 systemic lupus erythematosus MM DLBCL+2 more

…06916767Ethics Approval The study obtained ethics approval from Case Comprehensive Cancer Center, Cleveland Clinic’s Institutional Review Board (24-424/MOD01553…

560 Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in bilateral lung transplantation: case series

jitc · abstract · 2025-11-04 · 2 matching annotations

97.1%

Northwestern Memorial Hospital Northwestern University durvalumab atezolizumab bilateral non-small cell lung cancer toripalimab nivolumab COPD cemiplimab colorectal cancer+4 more

…o underwent bilateral orthotopic lung transplantation (BOLT) at Northwestern Memorial Hospital (Sep 2021-May 2025) after at least one cycle of ICI therapy. Pa…

580 Phase 1 study of mitotic checkpoint inhibitor BAL0891 in combination with tislelizumab (anti-PD-1 antibody) in patients with advanced solid tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

86.5%

Cancer Res 2025 BAL0891 tislelizumab triple-negative breast cancer TTK-CS-101

…2164. https://doi.org/10.1158/1538-7445.AM2025-2164Wang, et al. Cancer Res 2025;85(8_Supplement_1):2169. https://doi.org/10.1158/1538-7445.AM20…

582 First-in-human phase 1/2 study of the integrin αvβ8-blocking antibody CRB-601 in patients with solid tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

80.1%

Cedars-Sinai Medical Center Stephenson Cancer Center CRB-601 ovarian cancer head and neck squamous cell carcinoma melanoma

…University Hospital Cleveland University Hospitals IRB 20241088 Cedars-Sinai Medical Center Cedars-Sinai Office of Research Compliance and Quality Improvem…

583 Intrathecal PD-1 inhibitor combined with pemetrexed for leptomeningeal metastases from solid tumors: preliminary results from a phase I/II study (NCT 06462222)

jitc · abstract · 2025-11-04 · 2 matching annotations

91.2%

Guangzhou Medical University Affiliated Huizhou Hospital pemetrexed non-small cell lung cancer solid tumors small cell lung cancer Intrathecal PD-1 inhibitor breast cancer involved-field radiotherapy leptomeningeal metastases+1 more

… Institutional Review Board of the Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China (Approval number: 2024-KY-029-01). Informed con…